Brightpath Biotherapeutics completes payment for 20th stock acquisition rights

Brightpath Biotherapeutics announced the completion of payment for the issuance price of its 20th series of stock acquisition rights on December 8, 2025. The total payment amounted to JPY 1,375,000 for 275,000 units of stock acquisition rights, allotted to Phillip Securities Japan Ltd. Each stock acquisition right represents 100 shares.

The potential shares from this issuance could reach 27,500,000 shares, even at the lower exercise price limit of JPY 30. The initial exercise price is set at JPY 59. The exercise period for these rights is from December 9, 2025, to December 8, 2027.

The exercise price will be adjusted daily, starting from the next trading day after the allotment date, based on 100% of the closing price of Brightpath Biotherapeutics' common stock on the Tokyo Stock Exchange. However, the exercise price will not fall below the JPY 30 floor. The estimated total capital raised from this issuance is JPY 1,603,875,000, factoring in the issuance price and proceeds from the exercise of rights, less estimated expenses.